7S2Y

SAMHD1 HD domain bound to CNDAC

Summary for 7S2Y

• Entry DOI: 10.2210/pdb7s2y/pdb
• Descriptor: Deoxynucleoside triphosphate triphosphohydrolase SAMHD1, 4-amino-1-{2-cyano-2-deoxy-5-O-[(S)-hydroxy{[(S)-hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl]-beta-D-arabinofuranosyl}pyrimidin-2(1H)-one, 2'-DEOXYADENOSINE 5'-TRIPHOSPHATE, ... (6 entities in total)
• Functional Keywords: samhd1, inhibitor, sapacitabine, hydrolase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 4
• Total formula weight: 259926.05

Authors

Digianantonio, K.M.,Xiong, Y. (deposition date: 2021-09-04, release date: 2021-10-27, Last modification date: 2023-10-18)

Primary citation

Rothenburger, T.,Thomas, D.,Schreiber, Y.,Wratil, P.R.,Pflantz, T.,Knecht, K.,Digianantonio, K.,Temple, J.,Schneider, C.,Baldauf, H.M.,McLaughlin, K.M.,Rothweiler, F.,Bilen, B.,Farmand, S.,Bojkova, D.,Costa, R.,Ferreiros, N.,Geisslinger, G.,Oellerich, T.,Xiong, Y.,Keppler, O.T.,Wass, M.N.,Michaelis, M.,Cinatl Jr., J.
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
J Exp Clin Cancer Res, 40:317-317, 2021

PubMed Abstract: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1.

PubMed: 34641952
DOI: 10.1186/s13046-021-02093-4

Experimental method

X-RAY DIFFRACTION (2.8 Å)